Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Barley

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
AIDS (London, England)|April 21, 2010
HIV-1 viral protein r induces ERK and caspase-8-dependent apoptosis in renal tubular epithelial cellsAlexandra Snyder, Zygimantas C Alsauskas, Jeremy S Leventhal, et al.
Blood Advances|January 29, 2024
Regression of smoldering myeloma with treatment of Gaucher diseaseKevin Barley, Anshuman Parekh, Syed Salam, et al.
American Journal of Hematology|December 10, 2019
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m<sup>2</sup> in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m<sup>2</sup>Kevin Barley, Larysa Sanchez, Hearn J Cho, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
AIDS (London, England)|April 21, 2010
HIV-1 viral protein r induces ERK and caspase-8-dependent apoptosis in renal tubular epithelial cellsAlexandra Snyder, Zygimantas C Alsauskas, Jeremy S Leventhal, et al.
Blood Advances|January 29, 2024
Regression of smoldering myeloma with treatment of Gaucher diseaseKevin Barley, Anshuman Parekh, Syed Salam, et al.
American Journal of Hematology|December 10, 2019
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m<sup>2</sup> in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m<sup>2</sup>Kevin Barley, Larysa Sanchez, Hearn J Cho, et al.
Pageof 2